








Figure 1. Epidemic Curve, weeks 01 - 26










Figure 2. Quarterly Trends of Surveillance and Laboratory Performance Indicators




(1) — Percentage of cases with vaccination status known

Threshold: > 90%



(2) — Percentage of cases with CSF collected


Threshold: > 80%



(3)\* — Percentage of CSF specimen received at any lab in trans-isolate (T-I)


Threshold: > 50%

\*Togo: the protocol does not require the use of TI for 3 of the 4 hospitals because of their proximity to the lab.




(4) — Percentage of CSF specimens received at the NRL

Threshold: > 70%




(5) — Percentage of cases with a delay of <7 days between CSF collection date and date CSF received at NRL


Threshold: > 50%




(7) —Percentage of CSF specimen tested at labs other than the NRL by a Gram stain test  
Threshold: > 70%




(8) — Percentage of CSF specimen received at the NRL and analyzed by a confirmatory test (culture, PCR, latex or rapid diagnostic test)  
Threshold: > 90%



(9) — Percentage of CSF specimen contaminated for culture procedure at the NRL  
Threshold: < 10%



(10) — Percentage of CSF specimen contaminated for PCR procedure at the NRL  
Threshold: < 10%



(11) — Percentage of CSF confirmed at the NRL for Hi, Sp and Nm and other pathogens  
Threshold: > 30%

**Figure 3. Comparison between aggregate reporting and case-based surveillance data from MenAfriNet supported districts, weeks 01 - 26**

